Building on validated HIP technology, Sana Biotechnology is advancing SC451, a stem cell-derived therapy designed as a one-time treatment targeting normal blood glucose without exogenous insulin or ...
Building on validated HIP technology, Sana Biotechnology is advancing SC451, a stem cell-derived therapy designed as a one-time treatment targeting normal blood glucose without exogenous insulin or ...